Goldman Sachs’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-48,948
| Closed | -$557K | – | 6026 |
|
|
2023
Q4 | $557K | Buy |
+48,948
| New | +$385K | ﹤0.01% | 4693 |
|
|
2023
Q1 | – | Sell |
-11,160
| Closed | -$81K | – | 6361 |
|
|
2022
Q4 | $81K | Sell |
11,160
-1,497
| -12% | -$12.6K | ﹤0.01% | 5521 |
|
|
2022
Q3 | $123K | Sell |
12,657
-8,235
| -39% | -$154K | ﹤0.01% | 5632 |
|
|
2022
Q2 | $399K | Buy |
20,892
+4,735
| +29% | +$123K | ﹤0.01% | 5240 |
|
|
2022
Q1 | $803K | Buy |
16,157
+4,947
| +44% | +$256K | ﹤0.01% | 4996 |
|
|
2021
Q4 | $847K | Buy |
11,210
+2,470
| +28% | +$169K | ﹤0.01% | 4996 |
|
|
2021
Q3 | $690K | Sell |
8,740
-13,564
| -61% | -$1.36M | ﹤0.01% | 5001 |
|
|
2021
Q2 | $3.09M | Buy |
22,304
+17,884
| +405% | +$3.41M | ﹤0.01% | 3787 |
|
|
2021
Q1 | $925K | Buy |
4,420
+1,178
| +36% | +$236K | ﹤0.01% | 4679 |
|
|
2020
Q4 | $538K | Sell |
3,242
-56
| -2% | -$8.65K | ﹤0.01% | 4564 |
|
|
2020
Q3 | $560K | Sell |
3,298
-2,265
| -41% | -$327K | ﹤0.01% | 4426 |
|
|
2020
Q2 | $924K | Buy |
+5,563
| New | +$868K | ﹤0.01% | 4007 |
|
|
2020
Q1 | – | Sell |
-1,106
| Closed | -$164K | – | 5647 |
|
|
2019
Q4 | $164K | Sell |
1,106
-1,039
| -48% | -$158K | ﹤0.01% | 4944 |
|
|
2019
Q3 | $293K | Buy |
+2,145
| New | +$302K | ﹤0.01% | 4699 |
|
|
2019
Q2 | – | Sell |
-2,936
| Closed | -$278K | – | 5413 |
|
|
2019
Q1 | $278K | Buy |
+2,936
| New | +$386K | ﹤0.01% | 4665 |
|
Goldman Sachs's HARP Position: Q1 2024 in Review
Goldman Sachs sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 48,948 shares — an estimated $557K sold.
Goldman Sachs first reported a position in HARP in Q1 2019 and held it in 15 quarters. The position peaked at $3.09M in Q2 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Goldman Sachs reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Goldman Sachs sold 48,948 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $557K.
- Goldman Sachs first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 15 quarters.
- Goldman Sachs's Harpoon Therapeutics, Inc. Common Stock position peaked at $3.09M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.